TTPH Tetraphase Pharmaceuticals Inc.
NewsSee all news
-
Tetraphase Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Developments
XERAVA™ Carton Sales Grew over 30% Compared with Second Quarter of 2019 Increased Formulary Uptake, with a 99% Success Rate for all Formulary Reviews to Date -Company to Hold Conference Call Today at 4:30 PM
-
Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will
-
Tetraphase Pharmaceuticals Announces Completion of $8 Million Registered Direct Offering Priced At-the-Market
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections,
-
Tetraphase Pharmaceuticals Announces $8 Million Registered Direct Offering Priced At-the-Market
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today
-
Tetraphase Pharmaceuticals Announces Reverse Stock Split
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections,
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
Tetraphase Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Developments
XERAVA™ Carton Sales Grew over 30% Compared with Second Quarter of 2019 Increased Formulary Uptake, with a 99% Success Rate for all Formulary Reviews to Date -Company to Hold Conference Call Today at 4:30 PM
-
Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will
-
Tetraphase Pharmaceuticals Announces Completion of $8 Million Registered Direct Offering Priced At-the-Market
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections,
-
Tetraphase Pharmaceuticals Announces $8 Million Registered Direct Offering Priced At-the-Market
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today
-
Tetraphase Pharmaceuticals Announces Reverse Stock Split
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections,
-
Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) Data at IDWeek 2019
– Seven Abstracts Selected for Poster Presentations – Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection)
-
Tetraphase Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today